/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

VIRIDIAN THERAPEUTICS INC Share Price Today: Live Updates & Key Insights

VIRIDIAN THERAPEUTICS INC share price today is $28.41, up -0.73%. The stock opened at $28.065 against the previous close of $28.62, with an intraday high of $28.74 and low of $27.91.

VIRIDIAN THERAPEUTICS INC Share Price Chart

style
pb-0

VIRIDIAN THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

VIRIDIAN THERAPEUTICS INC Share Price Performance

$28.41 -0.0073(-0.73%) VRDN at 13 Mar 2026 03:48 PM Biotechnology
Lowest Today 27.91
Highest Today 28.74
Today’s Open 28.065
Prev. Close 28.62
52 Week High 34.29
52 Week Low 9.90
Day’s Range: Low 27.91 High 28.74
52-Week Range: Low 9.90 High 34.29
1 day return -
1 Week return +0.31
1 month return +1.9
3 month return -13.9
6 month return +57.97
1 year return +79.41
3 year return -1.47
5 year return +52.38
10 year return -

VIRIDIAN THERAPEUTICS INC Institutional Holdings

FMR Inc 14.07

Vanguard Group Inc 5.49

BlackRock Inc 5.31

Deep Track Capital, LP 5.26

Bellevue Group AG 4.26

Fairmount Funds Management LLC 3.83

VR Adviser, LLC 3.80

TANG CAPITAL MANAGEMENT LLC 2.78

Vanguard Total Stock Mkt Idx Inv 2.74

Fidelity Select Health Care 2.74

State Street Corp 2.50

T. Rowe Price Associates, Inc. 2.37

Novo A/S 2.33

Maverick Capital Ltd 2.16

Baker Bros Advisors LP 1.93

Wellington Management Company LLP 1.93

iShares Russell 2000 ETF 1.90

Eversept Partners, LP 1.88

AllianceBernstein L.P. 1.82

Fidelity Advisor Biotechnology I 1.74

Geode Capital Management, LLC 1.73

State Street® SPDR® S&P® Biotech ETF 1.63

Fidelity Advisor Health Care I 1.47

venBio Select Advisor LLC 1.47

Loomis, Sayles & Company LP 1.45

Kynam Capital Management, LP 1.44

Fidelity Small Cap Growth 1.24

Fidelity Select Biotechnology 1.05

US Small-Cap Growth II Equity Comp 1.04

T. Rowe Price New Horizons 1.03

Strategic Advisers Fidelity US TtlStk 0.93

Vanguard Institutional Extnd Mkt Idx Tr 0.90

MEDICAL BioHealth EUR Acc 0.89

Fidelity Stock Selector Small Cap 0.87

Loomis Sayles Small Cap Growth Instl 0.79

Fidelity Small Cap Index 0.77

Fidelity Series Small Cap Opps 0.74

JPM Global Healthcare C (acc) USD 0.74

FIAM Small Cap Core Composite 0.71

Candriam Eqs L Biotech C USD Cap 0.66

VIRIDIAN THERAPEUTICS INC Market Status

Strong Buy: 9

Buy: 5

Hold: 2

Sell: 0

Strong Sell: 0

VIRIDIAN THERAPEUTICS INC Fundamentals

Market Cap 2925.15 M

PB Ratio 4.957

PE Ratio 0.0

Enterprise Value 2233.25 M

Total Assets 899.42 M

Volume 1212628

VIRIDIAN THERAPEUTICS INC Company Financials

Annual Revenue FY23:347000 0.3M, FY22:1772000 1.8M, FY21:2963000 3.0M, FY20:1050000 1.1M, FY19:4461000 4.5M

Annual Profit FY23:null 0.0M, FY22:1772000 1.8M, FY21:2963000 3.0M, FY20:1050000 1.1M, FY19:4461000 4.5M

Annual Net worth FY23:-216659000 -216.7M, FY22:-125444000 -125.4M, FY21:-79416000 -79.4M, FY20:-110984000 -111.0M, FY19:-42420000 -42.4M

Quarterly Revenue Q3/2025:70570000 70.6M, Q2/2025:75000 0.1M, Q1/2025:72000 0.1M, Q3/2024:86000 0.1M, Q2/2024:72000 0.1M

Quarterly Profit Q3/2025:70570000 70.6M, Q2/2025:75000 0.1M, Q1/2025:72000 0.1M, Q3/2024:86000 0.1M, Q2/2024:-5719000 -5.7M

Quarterly Net worth Q3/2025:-34599000 -34.6M, Q2/2025:-100735000 -100.7M, Q1/2025:-86912000 -86.9M, Q3/2024:-76689000 -76.7M, Q2/2024:-64992999 -65.0M

About VIRIDIAN THERAPEUTICS INC & investment objective

Company Information Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Organisation Biotechnology

Employees 252

Industry Biotechnology

CEO Mr. Stephen F. Mahoney J.D., MBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow